Read previous post:
Evans: "The theory behind all our products is that we don't have to take them through the entire clinical development program to get them approved by the FDA because they are existing formulations and active ingredients and the FDA already has a safety profile related to these products."
Cantech Letter interviews Norman Evans, CFO of Cipher Pharmaceuticals

Risk is relative. In the middle part of the last-decade, when income trusts were all the rage, Mississauga's CML Healthcare,...